MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development
- PMID: 16129702
- PMCID: PMC1378109
- DOI: 10.1084/jem.20042469
MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development
Abstract
Patients with tuberous sclerosis complex (TSC) develop hamartomatous tumors showing loss of function of the tumor suppressor TSC1 (hamartin) or TSC2 (tuberin) and increased angiogenesis, fibrosis, and abundant mononuclear phagocytes. To identify soluble factors with potential roles in TSC tumorigenesis, we screened TSC skin tumor-derived cells for altered gene and protein expression. Fibroblast-like cells from 10 angiofibromas and five periungual fibromas produced higher levels of monocyte chemoattractant protein-1 (MCP-1) mRNA and protein than did fibroblasts from the same patient's normal skin. Conditioned medium from angiofibroma cells stimulated chemotaxis of a human monocytic cell line to a greater extent than conditioned medium from TSC fibroblasts, an effect blocked by neutralizing MCP-1-specific antibody. Overexpression of MCP-1 seems to be caused by loss of tuberin function because Eker rat embryonic fibroblasts null for Tsc2 (EEF Tsc2(-/-)) produced 28 times as much MCP-1 protein as did EEF Tsc2(+/+) cells; transient expression of WT but not mutant human TSC2 by EEF Tsc2(-/-) cells inhibited MCP-1 production; and pharmacological inhibition of the Rheb-mTOR pathway, which is hyperactivated after loss of TSC2, decreased MCP-1 production by EEF Tsc2(-/-) cells. Together these findings suggest that MCP-1 is an important paracrine factor for TSC tumorigenesis and may be a new therapeutic target.
Figures
Similar articles
-
Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.J Cutan Pathol. 2003 Mar;30(3):174-7. doi: 10.1034/j.1600-0560.2003.2o066.x. J Cutan Pathol. 2003. PMID: 12641776
-
Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis.J Cutan Pathol. 2001 Oct;28(9):470-5. doi: 10.1034/j.1600-0560.2001.028009470.x. J Cutan Pathol. 2001. PMID: 11553313
-
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.PLoS One. 2014 Oct 27;9(10):e104809. doi: 10.1371/journal.pone.0104809. eCollection 2014. PLoS One. 2014. PMID: 25347447 Free PMC article.
-
Proteins interacting with the tuberous sclerosis gene products.Amino Acids. 2004 Oct;27(2):119-28. doi: 10.1007/s00726-004-0119-z. Epub 2004 Sep 7. Amino Acids. 2004. PMID: 15351877 Review.
-
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.Oncogene. 2005 Nov 14;24(50):7475-81. doi: 10.1038/sj.onc.1209090. Oncogene. 2005. PMID: 16288294 Review.
Cited by
-
Application of angiogenesis to clinical dermatology.Adv Dermatol. 2008;24:89-103. doi: 10.1016/j.yadr.2008.09.010. Adv Dermatol. 2008. PMID: 19256307 Free PMC article. Review. No abstract available.
-
Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression.Sci Rep. 2023 Feb 27;13(1):3331. doi: 10.1038/s41598-023-30056-6. Sci Rep. 2023. PMID: 36849798 Free PMC article.
-
Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion.J Leukoc Biol. 2008 Sep;84(3):760-8. doi: 10.1189/jlb.1107756. Epub 2008 Jun 11. J Leukoc Biol. 2008. PMID: 18550788 Free PMC article.
-
Long-Term Effects of Sirolimus on Human Skin TSC2-Null Fibroblast‒Like Cells.J Invest Dermatol. 2021 Sep;141(9):2291-2299.e2. doi: 10.1016/j.jid.2021.02.754. Epub 2021 Mar 26. J Invest Dermatol. 2021. PMID: 33773987 Free PMC article.
-
Lymphangioleiomyomatosis and TSC2-/- cells.Lymphat Res Biol. 2010 Mar;8(1):59-69. doi: 10.1089/lrb.2009.0031. Lymphat Res Biol. 2010. PMID: 20235888 Free PMC article. Review.
References
-
- Sampson, J.R. 2003. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem. Soc. Trans. 31:592–596. - PubMed
-
- Li, Y., M.N. Corradetti, K. Inoki, and K.L. Guan. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29:32–38. - PubMed
-
- Webb, D.W., A. Clarke, A. Fryer, and J.P. Osborne. 1996. The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol. 135:1–5. - PubMed
-
- Penneys, N.S., K.J. Smith, and A.J. Nemeth. 1991. Factor XIIIa in the hamartomas of tuberous sclerosis. J. Dermatol. Sci. 2:50–54. - PubMed
-
- Nemeth, A.J., and N.S. Penneys. 1989. Factor XIIIa is expressed by fibroblasts in fibrovascular tumors. J. Cutan. Pathol. 16:266–271. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
